Literature DB >> 12846937

Probiotics, Irritable Bowel Syndrome, and Inflammatory Bowel Disease.

Martin H. Floch1.   

Abstract

Probiotics are live, microbial food supplements that benefit the host animal by improving intestinal microbial balance. Their major role in preventing and treating gastrointestinal disease appears to be from their effect on the immune process, protection against abnormal invasive bacteria, and in the production of short-chain fatty acids from starch and non-starch polysaccharides. Probiotic microorganisms are administered in food supplements and yogurts. They are also now sold in the form of capsules and powders. There is great variation in the microorganisms in the various supplements. It is important to understand that all probiotic products are different. Some contain a single organism and others contain multiple organisms. Therapeutic results have been achieved with various probiotics in different diseases. In the treatment of inflammatory bowel diseases (IBD), success has been reported with Escherichia coli Nissle strain in ulcerative colitis, and with a multiple organism product, VSL#3 (VSL Pharmaceuticals, Fort Lauderdale, FL), in Crohn's disease and pouchitis. Initial reports in irritable bowel syndrome (IBS) have resulted in encouraging results with the use of E. coli Nissle strain, and recently with multiple organism probiotic supplements. However, caution must still apply to the use of probiotics in IBD and IBS because the reports and the number of patients treated are limited.

Entities:  

Year:  2003        PMID: 12846937     DOI: 10.1007/s11938-003-0020-y

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  28 in total

Review 1.  Probiotics: effects on immunity.

Authors:  E Isolauri; Y Sütas; P Kankaanpää; H Arvilommi; S Salminen
Journal:  Am J Clin Nutr       Date:  2001-02       Impact factor: 7.045

2.  Functional foods: benefits, concerns and challenges-a position paper from the american council on science and health.

Authors:  Clare M Hasler
Journal:  J Nutr       Date:  2002-12       Impact factor: 4.798

3.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

Review 4.  Taxonomy and important features of probiotic microorganisms in food and nutrition.

Authors:  W H Holzapfel; P Haberer; R Geisen; J Björkroth; U Schillinger
Journal:  Am J Clin Nutr       Date:  2001-02       Impact factor: 7.045

5.  Mucosal flora in inflammatory bowel disease.

Authors:  Alexander Swidsinski; Axel Ladhoff; Annelie Pernthaler; Sonja Swidsinski; Vera Loening-Baucke; Marianne Ortner; Jutta Weber; Uwe Hoffmann; Stefan Schreiber; Manfred Dietel; Herbert Lochs
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

6.  Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment.

Authors:  S Ulisse; P Gionchetti; S D'Alò; F P Russo; I Pesce; G Ricci; F Rizzello; U Helwig; M G Cifone; M Campieri; C De Simone
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

7.  Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome.

Authors:  S Sen; M M Mullan; T J Parker; J T Woolner; S A Tarry; J O Hunter
Journal:  Dig Dis Sci       Date:  2002-11       Impact factor: 3.199

8.  Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.

Authors:  W Kruis; E Schütz; P Fric; B Fixa; G Judmaier; M Stolte
Journal:  Aliment Pharmacol Ther       Date:  1997-10       Impact factor: 8.171

9.  Increased colonic permeability in patients with ulcerative colitis: an in vitro study.

Authors:  P Nejdfors; Q Wang; M Ekelund; B R Weström; O Jansson; C L Lindström; B Karlsson; B Jeppsson
Journal:  Scand J Gastroenterol       Date:  1998-07       Impact factor: 2.423

10.  Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study.

Authors:  K Plein; J Hotz
Journal:  Z Gastroenterol       Date:  1993-02       Impact factor: 2.000

View more
  6 in total

Review 1.  Probiotics manipulate host cytokine response and induce antimicrobial peptides.

Authors:  I Trebichavský; I Splíchal
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

2.  Effect of special Hungarian probiotic kefir on faecal microflora.

Authors:  Mária Figler; Gyula Mózsik; Béla Schaffer; Beáta Gasztonyi; Pongrác Acs; Béla Szili; Regina Rab; Sándor Szakály
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

3.  VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis.

Authors:  Cong Dai; Chang-Qing Zheng; Fan-Ji Meng; Zheng Zhou; Li-Xuan Sang; Min Jiang
Journal:  Mol Cell Biochem       Date:  2012-10-23       Impact factor: 3.396

4.  Nutritional Therapy in Inflammatory Bowel Disease.

Authors:  Maria O'Sullivan; Colm O'Morain
Journal:  Curr Treat Options Gastroenterol       Date:  2004-06

5.  Two-weeks repeated-dose oral toxicity study of Pediococcus acidilactici J9 in a mice model.

Authors:  Mijung Lee; Jin-Young Chung; Ka Yeun Kim; Wooseok Im; Manho Kim
Journal:  BMC Microbiol       Date:  2020-12-09       Impact factor: 3.605

6.  Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells.

Authors:  Satya Prakash; Aleksandra Malgorzata Urbanska
Journal:  Biologics       Date:  2008-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.